TROG 97.01 - Bladder (Phase II) - TROG Cancer Research

By w.paterson
15 August, 2021
0 Comments

A Phase II Study of Trans-Urethral Resection Followed by Synchronous Chemo-Radiation in the Definitive Management of Localised Invasive TCC of the Urinary Bladder

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

24 June, 2025

TROG 2024 Annual Research Report highlights a year of achievements

LATEST NEWS: 24 JUNE 2025 The latest annual report

11 June, 2025

Trial Could Prove a Game-Changer for Treating High-Risk Skin Cancer

LATEST NEWS: 11 JUNE 2025 New findings from a

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Phase II Study of Trans-Urethral Resection Followed by Synchronous Chemo-Radiation in the Definitive Management of Localised Invasive TCC of the Urinary Bladder

TROG 98.01 – Rectal (Phase II)

TROG 96.07 – Merkel Cell – Skin

Related Post

TROG 2024 Annual Research Report highlights a year of achievements

Trial Could Prove a Game-Changer for Treating High-Risk Skin Cancer

TROG 97.01 – Bladder (Phase II)

A Phase II Study of Trans-Urethral Resection Followed by Synchronous Chemo-Radiation in the Definitive Management of Localised Invasive TCC of the Urinary Bladder

TROG 98.01 – Rectal (Phase II)

TROG 96.07 – Merkel Cell – Skin

Related Post

TROG 2024 Annual Research Report highlights a year of achievements

Trial Could Prove a Game-Changer for Treating High-Risk Skin Cancer